Search clinical trials for: Placebo for dapagliflozin

Total 70130 results

October 6 University
Cairo University; National Heart Institute, Egypt

Recruiting

Canagliflozin in Patients With Acute Decompansted Heart Failure (The CANA -AHF)

Diabetes Mellitus | Chronic Heart Failure | Acute Heart Failure

Egypt
Hospital de Clinicas de Porto Alegre
Vifor Pharma

Not yet recruiting

IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency (COMBINED-HF)

Heart Failure, Systolic | Iron Deficiencies

Brazil
Albina Nowak, MD

Not yet recruiting

Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients

Fabry Disease
Tor Biering-Sørensen

Recruiting

Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients With CKD (DECODE-CKD)

Chronic Kidney Diseases

Denmark
Mario Negri Institute for Pharmacological Research
AstraZeneca

Completed

Dapagliflozin in Non-diabetic Stage IV CKD (ADAPT)

Chronic Kidney Diseases

Italy
University Medical Center Groningen
AstraZeneca

Terminated

TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension (TIMOTHY)

Albuminuria

Netherlands
AstraZeneca

Completed

A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients (DAPACARD)

Diabetes Mellitus Type 2

Finland, Sweden
Kinderkrankenhaus auf der Bult

Completed

Phase 1 Study to Explore the Safety and Pharmacokinetics of DAPAglifozin in Adolescents and Adults With Type 1 Diabetes (DAPA-IIT1)

Type 1 Diabetes

Germany
AstraZeneca
Parexel; George Clinical Pty Ltd

Terminated

A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

Chronic Kidney Disease

United States, Taiwan, Germany, Hungary, Malaysia, Japan, Israel, Poland, Brazil, Ukraine, Argentina
Hospital General Universitario Gregorio Marañon
Instituto de Salud Carlos III; University of Navarra; Fundación para la Investigación...

Unknown

Effects of SGLT2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With HFpEF (CARDIA-STIFF)

Diabetes Mellitus, Type 2 | Heart Failure With Preserved Ejection Fraction

Spain
AstraZeneca
Bristol-Myers Squibb

Completed

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker

Type 2 Diabetes

Mexico, Russian Federation, Spain, United States, Canada, Puerto Rico, Hungary, Peru, Romania, Poland, Germany, Czech Republic, India, Colombia, Denmark, Finland
AstraZeneca
Bristol-Myers Squibb

Completed

Evaluation of Dapagliflozin Taken Twice-daily

Type 2 Diabetes

South Africa, Germany, Hungary, Romania, Slovakia, Switzerland, Ukraine
Alexandria University

Recruiting

Cognitive Protective Effect of Newer Antidiabetic Drugs

Type 2 Diabetes

Egypt
Hilda Elizabeth Macías Cervantes

Completed

Dapagliflozin Effects on Coronary Calcium and Epicardial Fat Assessed by Cardiotomography

Myocardial Infarction | Diabetes Mellitus, Type 2 | Unstable Angina | Diabete Type 2

Mexico
Amsterdam UMC, location VUmc
AstraZeneca

Completed

DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2 (DECREASE)

Obesity | Type 2 Diabetes Mellitus

Netherlands
University Health Network, Toronto
Sunnybrook Health Sciences Centre; MOUNT SINAI HOSPITAL

Recruiting

DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk (DAPA-SWEET)

Cardiovascular Risk Factor

Canada
Instituto Mexicano del Seguro Social
Germán Ramón Bautista López; Luis Jonathan González; Rodolfo Guardado Mendoza; Gabriel...

Completed

Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI) (DAPA-AMI)

Heart Failure | Angina, Unstable | Acute Myocardial Infarction | Cardiovascular Morbidity

Mexico
Saint Luke's Health System
AstraZeneca; George Clinical Pty Ltd; Saint Luke's Hospital of Kansas City

Completed

Dapagliflozin in Respiratory Failure in Patients With COVID-19 (DARE-19)

COVID-19

United States, Brazil, Argentina, India, Canada, Mexico, United Kingdom
Christopher Bell
AstraZeneca

Completed

Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?

Weight Loss

United States
Mohammad Hussien Tantawy Soliman

Recruiting

Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI

Myocardial Infarction

Egypt
IRCCS Azienda Ospedaliera Universitaria San Martino...
AstraZeneca

Recruiting

GLUcose Transport and REnalPROtection in Chronic Kidney Disease (GLUTREPRO)

Hypertension | Diabetes Mellitus, Type 2 | Chronic Kidney Disease

Italy
Oslo University Hospital
University Hospital of North Norway; Haukeland University Hospital; St. Olavs...

Recruiting

Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys?

Renal Failure | Kidney Transplant; Complications | Kidney Transplant Failure

Norway
Oslo University Hospital
Karolinska University Hospital; Aarhus University Hospital; Erasmus Medical Center and other collaborators

Recruiting

DAPAgliflozin for Renal Protection in Heart Transplant Recipients (DAPARHT)

Kidney Failure | Heart Transplant Failure

Netherlands, Sweden, Denmark, Norway
National Taiwan University Hospital

Recruiting

A Single Center, Randomized, Open Label, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Dapagliflozin in Subjects With Nonalcoholic Fatty Liver Disease

Fatty Liver

Taiwan
Mads Ersbøll

Recruiting

Dapagliflozin in Pulmonary Arterial Hypertension (DAPAH)

Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary Hypertension

Denmark
National Heart Centre Singapore
Duke-NUS Medical School (Singapore)

Completed

Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment (DAPA-Shuttle1)

Heart Failure | Diabetes Mellitus

Singapore
Mansoura University

Active, not recruiting

Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients

Chronic Kidney Diseases | Bone Diseases, Metabolic

Egypt
AstraZeneca
Bristol-Myers Squibb

Completed

A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes

United States, Canada, Mexico, Puerto Rico
AstraZeneca

Completed

Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.

Type 2 Diabetes Mellitus

Japan
AstraZeneca
Bristol-Myers Squibb

Completed

To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately

Type 2 Diabetes Mellitus

United Kingdom
AstraZeneca
Bristol-Myers Squibb

Completed

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

Type 2 Diabetes

United States, Canada, Mexico, Russian Federation
Hongchang Guo

Recruiting

Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery

Diabetes Mellitus, Type 2 | Cardiac Surgery

China
University Medical Center Groningen
AstraZeneca; Dutch Kidney Foundation

Enrolling by invitation

The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

Heart Failure | Death | Kidney Disease, Chronic | Kidney Failure | Renal Transplant Failure

Netherlands, Germany, Australia
Janssen Research & Development, LLC

Completed

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

United States
Instituto Nacional de Cardiologia Ignacio Chavez

Not yet recruiting

Empagliflozin for No-reflow Phenomenon in PCI for STEMI (EMPA-PCI)

STEMI | No-Reflow Phenomenon
Chinese University of Hong Kong

Recruiting

SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus

Chronic Hepatitis B

Hong Kong
Medical University of Vienna
Vienna Dialysis Center

Recruiting

SGLT2 Inhibition in Hemodialysis (DAPA-HD)

Diabetes Mellitus, Type 2 | Hemodialysis | Chronic Kidney Disease | Kidney Failure | Left Ventricular Hypertrophy

Austria
Postgraduate Institute of Medical Education and...

Recruiting

Efficacy of Dapagliflozin in Diabetes Associated Peripheral Neuropathy (DINE)

Diabetic Peripheral Neuropathy

India
Centre Hospitalier Universitaire Saint Pierre
AstraZeneca

Terminated

Effect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic Patients (DAPAMICRO)

Diabetes Mellitus, Type 2

Belgium
University of California, San Diego
Juvenile Diabetes Research Foundation

Completed

Dapagliflozin Effects on Hypoglycemia

Type1 Diabetes Mellitus

United States
The University of Hong Kong
Food and Health Bureau, Hong Kong

Completed

Effect of Empagliflozin on Liver Fat in Non-diabetic Patients

Non-alcoholic Fatty Liver Disease

Hong Kong
Janssen Research & Development, LLC
The George Institute for Global Health, Australia

Completed

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus (CANVAS-R)

Diabetes Mellitus, Type 2 | Albuminuria

Australia, France, Italy, Poland, Ukraine, United Kingdom, United States, China, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Malaysia, Canada, Netherlands, Korea, Republic of, New Zealand, Brazil, Russian Federation, Puerto... and more
Janssen Research & Development, LLC

Completed

A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)

Diabetes Mellitus, Type 1

United States, Canada
EnnovaBio Australia Pharmaceuticals Pty Ltd

Not yet recruiting

A First-in-Human SAD/MAD Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ENC1018 in Healthy Adult Subjects

Healthy
Dong-A ST Co., Ltd.

Completed

Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Type2 Diabetes

Korea, Republic of
Boehringer Ingelheim

Completed

Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA

Diabetes Mellitus, Type 2

Japan
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

Diabetes Mellitus, Type 2

United States
AstraZeneca

Completed

The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM

Type 1 Diabetes Mellitus

Japan
Fondazione Schena
University of Bari

Recruiting

Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. (CLIgAN)

Glomerulonephritis | Immunoglobulin A Nephropathy

Italy
ZYUS Life Sciences Inc.
Novotech (Australia) Pty Limited; ZYUS Life Sciences Australia Pty Ltd

Completed

Trichomylin® Safety, Tolerability & Pharmacokinetics in Healthy Adults and First in Human Osteoarthritis Pain Evaluation (HOPE)

Healthy | Osteoarthritis

Australia

Search clinical trials for: Placebo for dapagliflozin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations